- Business Wire•1 hour agoData Reinforcing the Long-Term Safety and Efficacy of Extended Half-Life Hemophilia Therapies ELOCTATE® and ALPROLIX® Highlighted at 58th ASH Meeting
Biogen and Swedish Orphan Biovitrum AB will present new data, including updated longitudinal safety and efficacy findings from phase 3 and extension studies, on the companies’ extended half-life therapies, ELOCTATE® for hemophilia A and ALPROLIX® for hemophilia B, at the 58th American Society of Hematology Annual ...
- Investopedia•20 hours ago
Biogen’s spinoff Bioverativ remains on track for public listing in early 2017, and gets two key hemoglobinopathy programs from Sangamo.
BIIB : Summary for Biogen Inc. - Yahoo Finance
Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||297.20 x 100|
|Ask||307.62 x 200|
|Day's Range||293.05 - 299.95|
|52 Week Range||223.02 - 333.65|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||16.81|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|